Cary Esselens

Cary Esselens

Auto-generated profile, based on publicly available information

Cary Esselens

VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Cell
Verified
Journal Article
Closed access
RSRagna Sannerud
Ragna Sannerud
CECary Esselens
Cary Esselens
PEPaulina Ejsmont
Paulina Ejsmont
RMRafael Mattera
Rafael Mattera
LRLeila Rochin
Leila Rochin
WAWim Annaert
Wim Annaert

1 August 2001 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CJChris De Jonghe
Chris De Jonghe
CECary Esselens
Cary Esselens
SKSamir Kumar-Singh
Samir Kumar-Singh
KCKatleen Craessaerts
Katleen Craessaerts
SSSally Serneels
Sally Serneels
BSBart De Strooper
Bart De Strooper
Release of amyloid β (Aβ) from the amyloid precursor protein (APP) requires cleavages by β- and γ-secretases and plays a crucial role in Alzheimer’s disease (AD) pathogenesis. Missense mutations in the APP gene causing familial AD are clustered around the β-, α- and particular γ-secretase cleavage sites. We systematically compare in primary neurons the effect on APP processing of a series of clinical APP mutations (two of which not characterized before) located in close proximity to the γ-secretase cleavage site. We confirm and extend previous observations showing that all these mutations (T714I, V715M, V715A, I716V, V717I and V717L) affect γ-secretase cleavage causing an increased relative ratio of Aβ42 to Aβ40. Taking advantage of these extended series of APP mutations we were able to demonstrate an inverse correlation between these ratios and the age at onset of the disease in the different families. In addition, a subset of mutations caused the accumulation of APP C-terminal fragments indicating that these mutations also influence the stability of APP C-terminal fragments. However, it is unlikely that these fragments contribute significantly to the disease process.

1 November 2001 in Neuron
Verified
Journal Article
Closed access
WAWim G Annaert
Wim G Annaert
CECary Esselens
Cary Esselens
VBVeerle Baert
Veerle Baert
CBChristine Boeve
Christine Boeve
GSGreet Snellings
Greet Snellings
BSBart De Strooper
Bart De Strooper

27 September 2004 in Journal of Cell Biology
Verified
Journal Article
Open access
CECary Esselens
Cary Esselens
VOViola Oorschot
Viola Oorschot
VBVeerle Baert
Veerle Baert
TRTim Raemaekers
Tim Raemaekers
KSKurt Spittaels
Kurt Spittaels
WAWim Annaert
Wim Annaert
Presenilin 1 (PS1) interacts with telencephalin (TLN) and the amyloid precursor protein via their transmembrane domain (Annaert, W.G., C. Esselens, V. Baert, C. Boeve, G. Snellings, P. Cupers, K. Craessaerts, and B. De Strooper. 2001. Neuron. 32:579–589). Here, we demonstrate that TLN is not a substrate for γ-secretase cleavage, but displays a prolonged half-life in PS1−/− hippocampal neurons. TLN accumulates in intracellular structures bearing characteristics of autophagic vacuoles including the presence of Apg12p and LC3. Importantly, the TLN accumulations are suppressed by adenoviral expression of wild-type, FAD-linked and D257A mutant PS1, indicating that this phenotype is independent from γ-secretase activity. Cathepsin D deficiency also results in the localization of TLN to autophagic vacuoles. TLN mediates the uptake of microbeads concomitant with actin and PIP2 recruitment, indicating a phagocytic origin of TLN accumulations. Absence of endosomal/lysosomal proteins suggests that the TLN-positive vacuoles fail to fuse with endosomes/lysosomes, preventing their acidification and further degradation. Collectively, PS1 deficiency affects in a γ-secretase–independent fashion the turnover of TLN through autophagic vacuoles, most likely by an impaired capability to fuse with lysosomes.

1 July 2009 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Joaquín ArribasJoaquín Arribas
Joaquín Arribas
CECary Esselens
Cary Esselens
As a metalloproteinase specialized in releasing membrane-tethered proteins, A Disintegrin and A Metalloproteinase 17 (ADAM17), also known as Tumor necrosis factor-α Converting Enzyme (TACE) or less commonly CD156q, has received more than its share of attention. This is mainly because major contemporary pathologies like cancer, inflammatory and vascular diseases seem to be connected to its cleavage abilities. The involvement in such a broad spectrum of diseases is due to the large variety of substrates that ADAM17 is able to cut. ADAM17 can activate growth factors or inactivate receptors by shedding their extracellular domain from the cell membrane. Similarly, it can detach cells by cleaving cell adhesion molecules. Some of these proteolytic events are part of cleavage cascades known as Regulated Intramembrane Proteolysis and lead to intracellular signaling. It is therefore clear that ADAM17 literally fulfills a key role in diverse processes and pathologies, making it a prime target for developing therapies. Here we review the role of ADAM17 in health and disease and highlight the problems to overcome for ADAM17 to mature towards a therapeutically valuable target.

1 July 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
JBJoan Josep Bech-Serra
Joan Josep Bech-Serra
BSBelén Santiago-Josefat
Belén Santiago-Josefat
CECary Esselens
Cary Esselens
PSPaul Saftig
Paul Saftig
JBJosé Baselga
José Baselga
FCFrancesc Canals
Francesc Canals
In contrast with the early view of metalloproteases as simple extracellular matrix-degrading entities, recent findings show that they are highly specific modulators of different signaling pathways involved, positively or negatively, in tumor development. Thus, before considering a given metalloprotease a therapeutic target, it seems advisable to characterize its function by identifying its repertoire of substrates. Here, we present a proteomic approach to identify ADAM17 substrates by difference gel electrophoresis. We found that the shedding of the extracellular domain of the transferrin receptor and those of two cell-cell adhesion molecules, activated leukocyte cell adhesion molecule (ALCAM) and desmoglein 2 (Dsg-2), is increased in cells overexpressing ADAM17. Genetic evidence shows that while ADAM17 is responsible for the shedding of ALCAM, both ADAM17 and ADAM10 can act on Dsg-2. Activation of the epidermal growth factor receptor leads to the upregulation of the shedding of Dsg-2 and to the concomitant upregulation of ADAM17, but not ADAM10, supporting the ability of overexpressed ADAM17 to shed Dsg-2. These results unveil a role of ADAM10 and ADAM17 in the shedding of cell-cell adhesion molecules. Since loss of cell adhesion is an early event in tumor development, these results suggest that ADAM17 is a useful target in anticancer therapy.